DS-8587 (Daiichi Sankyo (Japan) a new broad-spectrum antibacterial agent, is in phase I clinical trials for the treatment of bacterial infection.

DS-8587

Daiichi Sankyo (Japan)

7-[3a(R)-Amino-6a(S)-fluoroperhydrocyclopenta[c]pyrrol-2-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride dihydrate

7-[(1S,6S)-1-amino-4-oxa-8-azabicyclo[4.3.0]nonan-8-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid

C21 H22 F3 N3 O3 . Cl H . 2 H2 O
Mw	493.904

DS-8587, a new broad-spectrum antibacterial agent, is in phase I clinical trials at Daiichi Sankyo for the treatment of bacterial infection.

DS-8587, from Daiichi Sankyo, is a fluoroquinolone with improved activity against both Gram-negative and Gram-positive bacteria. The compound is especially effective against Acinetobacter baumannii  but also has improved activity against streptococci, staphylococci, enterococci, E. coli, and anaerobes . The compound is currently under Phase I of clinical development .

DS-8587, a new generation of fluoroquinolone, against Acinetobacter baumannii. The MICs against clinical isolates and inhibitory activity against target enzymes of DS-8587 was superior to ciprofloxacin and levofloxacin. Furthermore, the antibacterial activity of DS-8587 was less affected by adeA/adeB/adeC or abeM efflux pumps and frequency of single-step mutations with DS-8587 was lower as compared to those with ciprofloxacin. DS-8587 might be an effective agent against A. baumanniiinfection.

WO 2008082009 or

http://www.google.com/patents/EP2540715A1?cl=en

[Reference Example 71]

(3S)-3-[3-(tert-Butyldimethylsilyloxy)-1-propyl]-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester

• 
  
  

  
• [
  (3S)-3-(3-Hydroxy-1-propyl)-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester (46 g) and imidazole (11.9 g) were dissolved in dimethylformamide (600 mL). After addition of tert-butyldimethylsilyl chloride (23.2 g) under ice-cooling, the mixture was stirred at room temperature for 59.5 hours. The reaction solution was extracted with a 10% citric acid solution and ethyl acetate. Then, the organic layer was sequentially washed with saturated sodium bicarbonate water and brine, dried over anhydrous sodium sulfate, and filtered. Thereafter, the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate = 9:1 -> 8:2 -> 2:1) to give 29.7 g of the title compound as a pale yellow oil.
  ¹H-NMR (400 MHz, CDCl₃) δ: 7.37-7.22 (5H, m), 5.48 (1H, q, J=7.11 Hz), 3.58 (2H, t, J=6.13 Hz), 3.34 (1H, d, J=10.05 Hz), 3.12 (1H, d, J=10.05 Hz), 2.94 (1H, d, J=16.91 Hz), 2.31 (1H, d, J=17.16 Hz), 1.86-1.74 (1H, m), 1.72-1.62 (1H, m), 1.51 (3H, d, J=7.11 Hz), 1.49-1.24 (2H, m), 1.33 (9H, s), 0.88 (9H, s), 0.03 (6H, s).

[Reference Example 72]

(3S)-3-[3-(tert-Butyldimethylsilyloxy)-1-propyl]-4-fluoro-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester

• 
  
  
• 
  
  (3S)-3-[3-(tert-Butyldimethylsilyloxy)-1-propyl]-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester (30 g) was dissolved in tetrahydrofuran (280 mL), and the atmosphere was replaced with argon. Then, lithium hexamethyldisilazide (1.0 M solution in tetrahydrofuran) (78.0 mL) was added dropwise at -15°C, and the mixture was stirred at -5°C for 30 minutes. After cooling to -15°C again, a solution of N-fluorobenzenesulfonimide (26.6 g) in tetrahydrofuran (220 mL) was added dropwise, and the mixture was stirred at room temperature for 17 hours. The reaction solution was extracted with a 10% citric acid solution and ethyl acetate. Then, the organic layer was washed with brine, dried over anhydrous sodium sulfate, and filtered. Thereafter, the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate = 9:1 -> 8:2) to give 8.15 g of the title compound as a pale yellow solid. ¹H-NMR (400 MHz, CDCl₃) δ: 7.37-7.23 (5H, m), 5.53-5.44 (1H, m), 5.18 (1H, d, J=51.72 Hz), 3.64-3.52 (2H, m), 3.32-3.19 (2H, m), 1.92-1.65 (2H, m), 1.55 (3H, d, J=4.66 Hz), 1.33 (9H, s), 0.88 (9H, s), 0.03 (6H, s).
  MS (FAB) m/z: 480 (M+H)⁺.
  IR (ATR) ν: 3421, 2977, 2935, 2877, 1698, 1454, 1369, 1309, 1249, 1153, 1058, 1035, 1006, 842 cm^-1.

[Reference Example 73]

(3S)-4-Fluoro-3-(3-hydroxy-1-propyl)-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester

• 
  
  
• 
  
  (3S)-3-[3-(tert-Butyldimethylsilyloxy)-1-propyl]-4-fluoro-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester (8.15 g) was dissolved in tetrahydrofuran (25.0 mL). Acetic acid (22.0 mL) and tetrabutylammonium fluoride (1.0 M solution in tetrahydrofuran) (25.0 mL) were added under ice-cooling, and the mixture was stirred at room temperature for 21.5 hours. The reaction solution was extracted with a 10% citric acid solution and ethyl acetate. Then, the organic layer was sequentially washed with saturated sodium bicarbonate water and brine, dried over anhydrous sodium sulfate, and filtered. Thereafter, the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate = 9:1 -> 8:2 -> 1:1) to give 5.77 g of the title compound as a pale yellow oil.
  ¹H-NMR (400 MHz, CDCl₃) δ: 7.37-7.22 (5H, m), 5.48 (1H, q, J=7.03 Hz), 5.20 (1H, d, J=51.48 Hz), 3.69-3.59 (2H, m), 3.31-3.21 (2H, m), 1.95-1.72 (2H, m), 1.68-1.43 (2H, m), 1.56 (3H, d, J=7.11 Hz), 1.33 (9H, s).

[Reference Example 74]

(3S)-3-(3-benzenesulfonyloxy-1-propyl)-4-Fluoro-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester

• 
  
  
• 
  
  (3S)-4-Fluoro-3-(3-hydroxy-1-propyl)-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester (12.20 g) was dissolved in dichloromethane (400 mL). Benzenesulfonyl chloride (9.06 mL), triethylamine (10.7 mL), and 4-dimethylaminopyridine (2.04 g) were added under ice-cooling, and the mixture was stirred at room temperature for 12.5 hours. Saturated sodium bicarbonate water was added to the reaction solution, and the mixture was stirred for 30 minutes, followed by extraction with dichloromethane. The organic layer was sequentially washed with a 10% citric acid solution and brine, dried over anhydrous sodium sulfate, and filtered. Thereafter, the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate = 8:2 -> 1:1) to give 11.7 g of the title compound as a pale yellow oil.
  ¹H-NMR (400 MHz, CDCl₃) δ: 7.94 - 7.87 (2H, m), 7.71-7.63 (1H, m), 7.60-7.53 (2H, m), 7.37-7.23 (5H, m), 5.46 (1H, q, J=7.11 Hz), 5.15 (1H, d, J=51.48 Hz), 4.10-3.98 (2H, m), 3.26-3.15 (2H, m), 1.88-1.50 (4H, m), 1.55 (3H, s), 1.30 (9H, s).

[Reference Example 75]

(1S,5R)-5-Fluoro-4-oxo-3-[(1R)-1-phenylethyl]-3-azabicyclo[3.3.0]octan-1-ylcarboxylic acid tert-butyl ester

• 
  
  
• 
  
  (3S)-3-(3-benzenesulfonyloxy-1-propyl)-4-Fluoro-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxylic acid tert-butyl ester (10.9 g) was dissolved in tetrahydrofuran (350 mL), and the atmosphere was replaced with argon. Then, potassium hexamethyldisilazide (0.5 M solution in toluene) (86.5 mL) was added dropwise at - 15°C, and the mixture was stirred at 0°C for 1.5 hours. After cooling to -10°C, saturated aqueous ammonium chloride (100 mL) was added dropwise, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was extracted with a 10% citric acid solution and ethyl acetate. Then, the organic layer was washed with brine, dried over anhydrous sodium sulfate, and filtered. Thereafter, the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane:ethyl acetate = 9:1 -> 7:1) to give 4.36 g of the title compound as a pale yellow solid.
  ¹H-NMR (400 MHz, CDCl₃) δ: 7.38-7.25 (5H, m), 5.58-5.49 (1H, m), 3.63 (1H, d, J=10.3 Hz), 2.91 (1H, dd, J=10.3, 3.2 Hz), 2.67-2.56 (1H, m), 2.50-2.38 (1H, m), 2.26-2.09 (1H, m), 2.06-1.94 (1H, m), 1.74-1.66 (1H, m), 1.54 (3H, d, J=7.1 Hz), 1.50-1.40 (1H, m), 1.34 (9H, s).

[Reference Example 76]

(1R,5R)-1-(tert-Butoxycarbonylamino)-5-fluoro-4-oxo-3-[(1R)-1-phenylethyl]-3-azabicyclo[3.3.0]octane

• 
  
  

  
• 
  
  (1S,5R)-5-Fluoro-4-oxo-3-[(1R)-1-phenylethyl]-3-azabicyclo[3.3.0]octan-1-ylcarboxylic acid tert-butyl ester (4.36 g, 12.5 mmol) was dissolved in dichloromethane (70 mL). Trifluoroacetic acid (70 mL) was added dropwise, and the mixture was stirred at room temperature for six hours. The solvent was evaporated under reduced pressure, and then the residue was azeotropically distilled with toluene to give carboxylic acid (3.70 g).
• 
  
  The resulting carboxylic acid was dissolved in toluene. Triethylamine (3.51 mL, 25.2 mmol) and diphenylphosphoryl azide (2.98 ml, 13.8 mmol) were added, and the mixture was heated to reflux for five hours. The solvent was evaporated under reduced pressure. Then, 1,4-dioxane (110 ml) and 6N hydrochloric acid (110 mL) were added to the residue, and the mixture was stirred at 60°C for 2.5 hours. After extraction with water and ethyl acetate, the aqueous layer was made alkaline with a saturated sodium hydroxide solution and extracted with chloroform twice. The organic layers were combined, dried over anhydrous sodium sulfate, and filtered, and then the solvent was evaporated under reduced pressure. Di-tert-butyl dicarbonate (11.05 g) was added to the residue, and the mixture was stirred at 75°C for six hours. The reaction solution was concentrated under reduced pressure, and then the residue was subjected to silica gel column chromatography (hexane:ethyl acetate = 9:1 -> 1:1) to give 3.69 g of the title compound as a pale yellow oil.
  ¹H-NMR (400 MHz, CDCl₃) δ: 7.37-7.23 (5H, m), 5.50 (1H, q, J=7.1 Hz), 5.22 (1H, brs), 3.34 (2H, s), 2.49-2.37 (1H, m), 2.32-2.03 (3H, m), 2.02-1.90 (1H, m), 1.51 (3H, d, J=7.1 Hz), 1.55-1.48 (1H, m), 1.35 (9H, s).

[Reference Example 77]

(1R,5S)-1-(tert-Butoxycarbonylamino)-5-fluoro-3-[(1R)-1-phenylethyl]-3-azabicyclo[3.3.0]octane

• 
  
  
• 
  
  (1R,5R)-1-(tert-Butoxycarbonylamino)-5-fluoro-4-oxo-3-[(1R)-1-phenylethyl]-3-azabicyclo[3.3.0]octane (3.69 g, 10.2 mmol) was dissolved in tetrahydrofuran (200 mL). A 1.20 M solution of a borane-tetrahydrofuran complex in tetrahydrofuran (42.4 mL, 50.9 mmol) was added dropwise under ice-cooling, and the mixture was stirred for two hours while gradually heating to room temperature. The solvent was evaporated under reduced pressure. Under ice-cooling, 90% aqueous ethanol (100 mL) and triethylamine (100 mL) were added to the residue, and the mixture was heated to reflux for two hours. The solvent was evaporated under reduced pressure, and then the residue was extracted with saturated sodium bicarbonate water and dichloromethane. Thereafter, the target substance was extracted from the aqueous layer with dichloromethane. The organic layers were combined, washed with brine, and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under reduced pressure, and the resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate = 95:5 -> 90:10) to give 3.33 g of the title compound as a pale yellow oil.
  ¹H-NMR (400 MHz, CDCl₃) δ: 7.32 - 7.18 (5H, m), 5.38 (1H, brs), 3.22 (1H, q, J=6.37 Hz), 2.92-2.57 (4H, m), 2.12-1.86 (4H, m), 1.80-1.67 (1H, m), 1.63-1.52 (3H, m), 1.42 (9H, s), 1.32 (3H, d, J=6.37 Hz)

[Reference Example 78]

(1R,5S)-1-(tert-Butoxycarbonylamino)-5-fluoro-3-azabicyclo[3.3.0]octane

• 
  
  
• 
  
  (1R,5S)-1-(tert-Butoxycarbonylamino)-5-fluoro-3-[(1R)-1-phenylethyl]-3-azabicyclo[3.3.0]octane (700 mg, 2.0 mmol) was dissolved in ethanol (30 mL). 10% palladium-carbon (50% wet) (1.01 g) was added, and the mixture was stirred in a hydrogen atmosphere at 50°C for 15 hours. The catalyst was removed by filtration, and then the filtrate was concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (dichloromethane:methanol = 98:2 -> 95:5) to give 446 mg of the title compound as a pale yellow solid.
  [α]_D ²³-15° (c=0.100, MeOH).
  ¹H-NMR (400 MHz, CDCl₃) δ: 5.29 (1H, brs), 3.47-3.18 (2H, m), 2.93-2.79 (2H, m), 2.15-1.71 (6H, m), 1.45 (9H, s).

[Example 17]

7-[(1R,5S)-1-Amino-5-fluoro-3-azabicyclo[3.3.0]octan-3-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropane]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid

• 
  
  
• 
  
  Triethylamine (0.215 mL, 1.54 mmol) and 6,7-difluoro-1-[(1R,2S)-2-fluorocyclopropane]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid-BF₂ chelate (530 mg, 1.53 mmol) were added to a solution of (1R,5S)-1-(tert-butoxycarbonylamino)-5-fluoro-3-azabicyclo[3.3.0]octane (250 mg, 1.02 mmol) in dimethyl sulfoxide (5.0 mL). The mixture was stirred at room temperature for seven days. Triethylamine (0.215 mL, 1.54 mmol) and 6,7-difluoro-1-[(1R,2S)-2-fluorocyclopropane]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid-BF₂ chelate (530 mg, 1.53 mmol) were further added to the reaction solution, and the mixture was stirred at room temperature for seven days. Triethylamine (0.215 mL, 1.54 mmol) and 6,7-difluoro-1-[(1R,2S)-2-fluorocyclopropane]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid-BF₂ chelate (530 mg, 1.53 mmol) were further added to the reaction solution, and the mixture was stirred at room temperature for ten days. Ethanol (6.0 mL), water (2.0 mL), and triethylamine (2.0 mL) were added to the reaction solution, and the mixture was stirred at 80°C for one hour. The solvent was evaporated under reduced pressure, and then the residue was extracted with a 10% citric acid solution and ethyl acetate. Then, the organic layer was washed with water twice and brine, dried over anhydrous sodium sulfate, and filtered. Thereafter, the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (dichloromethane:methanol = 98:2), and the resulting fraction was concentrated under reduced pressure. Then, the residue was dissolved in concentrated hydrochloric acid (3.5 mL) under ice-cooling, and the solution was stirred at room temperature for one hour. The reaction solution was washed with chloroform five times, and then the aqueous layer was adjusted to pH 12 with a saturated sodium hydroxide solution. The basic solution was adjusted to pH 7.4 with hydrochloric acid, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and filtered, and then the solvent was evaporated under reduced pressure. The resulting residue was purified by PTLC (developed with the lower layer of chloroform:methanol:water = 7:3:1). The resulting residue was solidified with isopropanol to give 7.1 mg of the title compound as a pale yellow solid.
• ¹H-NMR (400 MHz, 0.1N NaOD) δ: 8.50 (1H, s), 7.77 (1H, d, J=13.73 Hz), 5.80-4.80 (1H, m), 4.22-4.10 (1H, m), 3.99-3.85 (1H, m), 3.68-3.47 (2H, m), 3.43-3.34 (1H, m), 2.68 (3H, s), 2.21-1.98 (3H, m), 1.97-1.56 (4H, m), 1.42-1.23 (1H, m).
  MS (FAB); m/z: 422 (M+H)⁺.
  Anal.Calcd C₂₁H₂₂F₃N₃O₃·0.5H₂O·0.25IPA: C, 58.65; H, 5.66; F, 12.80; N, 9.43. Found: C, 58.63; H, 5.35; F, 12.35; N, 9.22.
  IR (ATR) ν: 2971, 2856, 1722, 1614, 1450, 1432, 1322, 1132, 1097, 987, 954, 929, 887, 856, 804 cm^-1.

WO 2012018105

http://www.google.st/patents/WO2012018105A1?cl=en

The following structural formula

compound represented by, 7 - [(1R, 5S) -1 - amino-5 - fluoro-3 - azabicyclo [3.3.0] octan-3 - yl] -6 - fluoro -1 - [(1R, . the 2S) -2 - fluoro-cyclopropane-1 - yl] -1,4 - dihydro-8 - methyl-4 - oxo-3-quinoline -) is referred to as carboxylic acid (hereinafter referred to as Compound A multi-agent containing quinolone resistance including resistant Gram-positive cocci resistant pneumococcus, etc., widely against gram-negative bacteria from Gram-positive bacteria, and, in addition to show strong antibacterial activity, convulsions, which is known in the art as a side effect of the antimicrobial agent of the present system potential cardiotoxicity light and toxicity-inducing activity (photosensitivity), has been reported recently in clinical further (QT prolongation), blood sugar abnormalities, and to express the side effects of delayed-type drug 疹等 is excellent safety low, Then, it is excellent oral absorbability and organ migration properties become apparent, is expected as an antimicrobial agent superior (Patent Document 1).

WO 2008/082009 pamphlet

The compound A, was synthesized according to the method described in Patent Document 1.
Preparation 7 1 hydrochloride dihydrate Ratings (1) Compound A crystalline acid addition salt preparation of acid addition salts of (Example 1) Compound A, and Compound A - [(1R, 5S) - 1 - amino-5 - fluoro-3 - azabicyclo [3.3.0] octan-3 - yl] -6 - fluoro -1 - [(1R, 2S) -2 - fluoro-cyclo-1 - yl] -1 , 4 - dihydro-8 - methyl-4 - oxo-3-quinoline - was added 1mol / L hydrochloric acid (74μL) carboxylic acid (Compound A) (31.3mg,, 0.074mmol) in, and dried under reduced pressure at room temperature.10% aqueous 2 the residue - was added to (100μL) propanol was dissolved by heating at 60 ℃, and allowed to stand day out on the room temperature. Collected by filtration the precipitated crystals, and the 1st air dried, 19.9mg (yield: 54%) was obtained.
Elemental analysis: C ₂₁ H ₂₂ F ₃ N ₃ O ₃ · HCl · 2H ₂ O
Theoretical value: C; 51.07, H; 5.51, N; 8.51, F; 11.54, Cl; 7.18
Measured value: C; 50.93, H; 5.40, N; 8.49, F; 11.30, Cl; 7.47

The characteristic diffraction peaks in the powder X-ray diffraction: 2θ = 5.3,7.9,10.6,13.3,21.1,23.0,25.1,27.6 (°)
2 5% aqueous (1001.6mg, 0.746mmol) in the preparation of Compound A one hydrochloride monohydrate (2) Compound A - was added propanol (30mL), was dissolved by heating at 60 ℃. After stirring day out on the room temperature and stirred for 6 hours at 10 ℃. Collected by filtration the precipitated crystals, and the 1st dried air, 839.3 mg (yield: 87%) was obtained.
Elemental analysis: C ₂₁ H ₂₂ F ₃ N ₃ O ₃ · HCl · 1H ₂ O
Theoretical value: C; 53.00, H; 5.30, N; 8.83, F; 11.98, Cl; 7.45
Measured value: C; 53.25, H; 5.43, N; 8.51, F; 11.58, Cl; 7.18
The characteristic diffraction peaks in the powder X-ray diffraction: 2θ = 11.3,14.0,20.1,21.4,22.8,24.0,26.0,26.6 (°)

ref

1. Higuchi, S.; Onodera, Y.; Chiba, M.; Hoshino, K.; Gotoh, N. Potent in vitro antibacterial activity of DS-8587, a new generation of broad spectrum quinolone, against Acinetobacter baumannii. Antimicrob. Agents Chemother. 2013, doi:10.1128/AAC.02374-12.
2. Daiichi Sankyo. Major R&D pipeline as of July, 2013. Available online: http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf (accessed on 28 September 2013).

EP0343524A1	May 19, 1989	Nov 29, 1989	Shionogi Seiyaku Kabushiki Kaisha	Pyridonecarboxylic acids and antibacterial agents
JPH0395176A				Title not available
JPH02231475A				Title not available
JPH08225567A				Title not available
JPS6345261A				Title not available
JPS6456673A				Title not available
JPS61282382A				Title not available
US5017708 *	Sep 8, 1989	May 21, 1991	Shionogi & Co., Ltd.	Azabicycloalkanes
WO1994014794A1	Dec 28, 1993	Jul 7, 1994	Hideki Ao	8-methoxyquinolonecarboxylic acid derivative
WO1995021163A1	Feb 2, 1995	Aug 10, 1995	Katsumi Chiba	Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor
WO1996023782A1	Feb 1, 1996	Aug 8, 1996	Daiichi Seiyaku Co	Heterocyclic compounds

1, nemonoxacin; 2, delafloxacin; 3, finafloxacin; 4, zabofloxacin; 5, JNJ-Q2; 6, DS-8587; 7, KPI-10; 8, ozenoxacin; 9, chinfloxacin; 10, ACH-702.